The article provides a correction regarding the BNT162b2 vaccine, confirming that it induces both neutralizing antibodies and poly-specific T cell responses in humans. These immune responses are critical for effective protection against infections. The findings affirm the vaccine's capability to create a robust immune profile, essential for combating diseases. The correction ensures that the scientific community has accurate information about the vaccine's immunogenicity, emphasizing the importance of continuous validation in vaccine research and development.
The BNT162b2 vaccine is demonstrated to induce neutralizing antibodies along with poly-specific T cell responses in human subjects, contributing to a robust immune response.
This correction confirms that the previously reported findings on the immunogenicity of the BNT162b2 vaccine are accurate and underlines its effectiveness in generating a multi-faceted immune response.
Collection
[
|
...
]